Specific induction of CD33 expression by E2A-HLF: The first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor

Leukemia

Volumn 24, Issue 4, 2010, Pages 865-869

  Akahane, K ^a   Inukai, T ^a   Inaba, T ^b   Kurosawa, H ^c   Look, A T ^d   Kiyokawa, N ^e   Fujimoto, J ^e   Goto, H ^f   Endo, M ^g   Zhang, X ^a   Hirose, K ^a   Kuroda, I ^a   Honna, H ^a   Kagami, K ^a   Goi, K ^a   Nakazawa, S ^a   Sugita, K ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; HYBRID PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR E2A HEPATIC LEUKEMIA FACTOR FUSION PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 19; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HUMAN; LETTER; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

EID: 77950928164     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.8     Document Type: Letter

References (8)

1. Wiersma SR, Ortega J, Sobel E, Weinberg KI. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800-808.
2. Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198-202.
3. Mejstrikova E, Kalina T, Trka J, Stary J, Hrusak O. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia 2005; 19: 1092-1094.
4. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483-490.
5. Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288-296.
6. Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531-534.
7. Bodger MP, Hart DN. Molecular cloning and functional analysis of the CD33 promotor. Br J Haematol 1998; 102: 986-995.
8. van der Velden AHJ, te Marvelde JG, Hoogeveen PG. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.